These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

310 related articles for article (PubMed ID: 31721068)

  • 21. The role of the adaptive immune system in burn-induced heterotopic ossification and mesenchymal cell osteogenic differentiation.
    Ranganathan K; Agarwal S; Cholok D; Loder S; Li J; Sung Hsieh HH; Wang SC; Buchman SR; Levi B
    J Surg Res; 2016 Nov; 206(1):53-61. PubMed ID: 27916375
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Fibrodysplasia ossificans progressiva. A case report and focus on the BMP signaling pathway.
    Bouvard B; Masson C; Legrand E; Audran M
    Morphologie; 2016 Dec; 100(331):250-255. PubMed ID: 26948676
    [TBL] [Abstract][Full Text] [Related]  

  • 23. An mTOR Signaling Modulator Suppressed Heterotopic Ossification of Fibrodysplasia Ossificans Progressiva.
    Hino K; Zhao C; Horigome K; Nishio M; Okanishi Y; Nagata S; Komura S; Yamada Y; Toguchida J; Ohta A; Ikeya M
    Stem Cell Reports; 2018 Nov; 11(5):1106-1119. PubMed ID: 30392977
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Histocompatibility antigens in patients with ectopic ossification due to fibrodysplasia ossificans progressiva.
    Connor JM; Woodrow JC; Evans DA
    Ann Rheum Dis; 1982 Dec; 41(6):646-7. PubMed ID: 6816154
    [No Abstract]   [Full Text] [Related]  

  • 25. The traumatic bone: trauma-induced heterotopic ossification.
    Dey D; Wheatley BM; Cholok D; Agarwal S; Yu PB; Levi B; Davis TA
    Transl Res; 2017 Aug; 186():95-111. PubMed ID: 28668522
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Acquired and congenital forms of heterotopic ossification: new pathogenic insights and therapeutic opportunities.
    Pacifici M
    Curr Opin Pharmacol; 2018 Jun; 40():51-58. PubMed ID: 29614433
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Hints on transcriptional control of essential players in heterotopic ossification of Fibrodysplasia Ossificans Progressiva.
    Ravazzolo R; Cappato S; Bocciardi R
    Bone; 2018 Apr; 109():187-191. PubMed ID: 29100956
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Clinical-pathological correlations in three patients with fibrodysplasia ossificans progressiva.
    Wentworth KL; Bigay K; Chan TV; Ho JP; Morales BM; Connor J; Brooks E; Shahriar Salamat M; Sanchez HC; Wool G; Pignolo RJ; Kaplan FS; Hsiao EC
    Bone; 2018 Apr; 109():104-110. PubMed ID: 29033382
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Analog Method for Radiographic Assessment of Heterotopic Bone in Fibrodysplasia Ossificans Progressiva.
    Rajapakse CS; Lindborg C; Wang H; Newman BT; Kobe EA; Chang G; Shore EM; Kaplan FS; Pignolo RJ
    Acad Radiol; 2017 Mar; 24(3):321-327. PubMed ID: 27989444
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The Expansion of Heterotopic Bone in Fibrodysplasia Ossificans Progressiva Is Activin A-Dependent.
    Upadhyay J; Xie L; Huang L; Das N; Stewart RC; Lyon MC; Palmer K; Rajamani S; Graul C; Lobo M; Wellman TJ; Soares EJ; Silva MD; Hesterman J; Wang L; Wen X; Qian X; Nannuru K; Idone V; Murphy AJ; Economides AN; Hatsell SJ
    J Bone Miner Res; 2017 Dec; 32(12):2489-2499. PubMed ID: 28782882
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Potent inhibition of heterotopic ossification by nuclear retinoic acid receptor-γ agonists.
    Shimono K; Tung WE; Macolino C; Chi AH; Didizian JH; Mundy C; Chandraratna RA; Mishina Y; Enomoto-Iwamoto M; Pacifici M; Iwamoto M
    Nat Med; 2011 Apr; 17(4):454-60. PubMed ID: 21460849
    [TBL] [Abstract][Full Text] [Related]  

  • 32. A new era for fibrodysplasia ossificans progressiva: a druggable target for the second skeleton.
    Kaplan FS; Glaser DL; Pignolo RJ; Shore EM
    Expert Opin Biol Ther; 2007 May; 7(5):705-12. PubMed ID: 17477807
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Response to comment on 'Palovarotene reduces heterotopic ossification in juvenile FOP mice but exhibits pronounced skeletal toxicity'.
    Goldhamer DJ; Lees-Shepard JB
    Elife; 2019 Jan; 8():. PubMed ID: 30698142
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Fibrodysplasia ossificans progressiva: a current review of imaging findings.
    Bauer AH; Bonham J; Gutierrez L; Hsiao EC; Motamedi D
    Skeletal Radiol; 2018 Aug; 47(8):1043-1050. PubMed ID: 29445932
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Palovarotene inhibits connective tissue progenitor cell proliferation in a rat model of combat-related heterotopic ossification.
    Wheatley BM; Cilwa KE; Dey D; Qureshi AT; Seavey JG; Tomasino AM; Sanders EM; Bova W; Boehm CA; Iwamoto M; Potter BK; Forsberg JA; Muschler GF; Davis TA
    J Orthop Res; 2018 Apr; 36(4):1135-1144. PubMed ID: 28960501
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Surgical treatment combined with NSAIDs in fibrodysplasia ossificans progressiva.
    Seok Y; Cho S; Lee E
    Ann Thorac Cardiovasc Surg; 2012; 18(1):61-3. PubMed ID: 21959193
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The role of Activin A in fibrodysplasia ossificans progressiva: a prominent mediator.
    Lin H; Shi F; Gao J; Hua P
    Biosci Rep; 2019 Aug; 39(8):. PubMed ID: 31341010
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [Fibrodysplasia ossificans progressiva. Report of one case].
    Contreras-Olea O; Goecke-Hochberger C; Rumié-Carmi HK; Lobo-Avilés R; Mellado-Sagredo C; Avila-Smirnow D
    Rev Med Chil; 2019 Mar; 147(3):384-389. PubMed ID: 31344178
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Palovarotene: First Approval.
    Hoy SM
    Drugs; 2022 Apr; 82(6):711-716. PubMed ID: 35384641
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Conserved signaling pathways underlying heterotopic ossification.
    Kan C; Chen L; Hu Y; Ding N; Lu H; Li Y; Kessler JA; Kan L
    Bone; 2018 Apr; 109():43-48. PubMed ID: 28455214
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 16.